Amneal Pharmaceuticals (AMRX) Non-Current Assets (2017 - 2026)

Amneal Pharmaceuticals has reported Non-Current Assets for 10 years, with the latest figure at $1.8 billion in Q2 2026.

• On a quarterly basis, Non-Current Assets changed 0.48% year-over-year to $1.8 billion in Q2 2026; TTM through Jun 2026 was $7.1 billion, a 6.01% decrease from a year earlier, with the FY2025 full-year figure at $1.8 billion, down 7.66% from the prior year.
• Non-Current Assets was $1.8 billion for Q2 2026 at Amneal Pharmaceuticals, up from $1.7 billion in the prior quarter.
• The five-year high for Non-Current Assets was $2.5 billion in Q1 2022, with the low at $1.7 billion in Q1 2026.
• Average Non-Current Assets over 5 years is $2.1 billion, with a median of $2.1 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets advanced 4.12% in 2022, then fell 12.7% in 2024.
• Over 5 years, Non-Current Assets stood at $2.4 billion in 2022, then dropped by 12.26% to $2.1 billion in 2023, then fell by 8.64% to $1.9 billion in 2024, then slipped by 7.66% to $1.8 billion in 2025, then grew by 3.52% to $1.8 billion in 2026.
• The last three Non-Current Assets figures came in at $1.8 billion (Q2 2026), $1.7 billion (Q1 2026), and $1.8 billion (Q4 2025), per Business Quant data.